223 related articles for article (PubMed ID: 31734255)
21. MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway.
Dong Y; Liang G; Yuan B; Yang C; Gao R; Zhou X
Tumour Biol; 2015 Mar; 36(3):1477-86. PubMed ID: 25431257
[TBL] [Abstract][Full Text] [Related]
22. Clinical value of lncRNA MALAT1 as a prognostic marker in human cancer: systematic review and meta-analysis.
Tian X; Xu G
BMJ Open; 2015 Sep; 5(9):e008653. PubMed ID: 26423854
[TBL] [Abstract][Full Text] [Related]
23. The role of vascular endothelial growth factor as a prognostic and clinicopathological marker in osteosarcoma: a systematic review and meta-analysis.
Zhang C; Wang L; Xiong C; Zhao R; Liang H; Luo X
J Orthop Surg Res; 2021 Dec; 16(1):738. PubMed ID: 34963495
[TBL] [Abstract][Full Text] [Related]
24. Clinical prognostic value of metastasis-associated lung adenocarcinoma transcript 1 in various human cancers: an updated meta-analysis.
Li Y; Yang Z; Wan X; Zhou J; Zhang Y; Ma H; Bai Y
Int J Biol Markers; 2016 May; 31(2):e173-82. PubMed ID: 26847605
[TBL] [Abstract][Full Text] [Related]
25. Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy.
Wang Z; Liu Z; Wu S
Oncotarget; 2017 May; 8(19):31465-31477. PubMed ID: 28415557
[TBL] [Abstract][Full Text] [Related]
26. LncRNA SOX2-OT is a novel prognostic biomarker for osteosarcoma patients and regulates osteosarcoma cells proliferation and motility through modulating SOX2.
Wang Z; Tan M; Chen G; Li Z; Lu X
IUBMB Life; 2017 Nov; 69(11):867-876. PubMed ID: 28960757
[TBL] [Abstract][Full Text] [Related]
27. High expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival.
Wang Z; Katsaros D; Biglia N; Shen Y; Fu Y; Loo LWM; Jia W; Obata Y; Yu H
Breast Cancer Res Treat; 2018 Sep; 171(2):261-271. PubMed ID: 29845475
[TBL] [Abstract][Full Text] [Related]
28. Elevated long noncoding RNA HAGLROS expression correlates with clinical progression and prognosis in osteosarcoma.
Wu PF; Dai ZT; Liu WD; Zhao ZX; Kong YH
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1428-1433. PubMed ID: 30840263
[TBL] [Abstract][Full Text] [Related]
29. LncRNAs act as prognostic and diagnostic biomarkers in renal cell carcinoma: a systematic review and meta-analysis.
Chen J; Chen Y; Gu L; Li X; Gao Y; Lyu X; Chen L; Luo G; Wang L; Xie Y; Duan J; Peng C; Ma X
Oncotarget; 2016 Nov; 7(45):74325-74336. PubMed ID: 27527868
[TBL] [Abstract][Full Text] [Related]
30. Correlation of increased MALAT1 expression with pathological features and prognosis in cancer patients: a meta-analysis.
Shi XS; Li J; Yang RH; Zhao GR; Zhou HP; Zeng WX; Zhou M
Genet Mol Res; 2015 Dec; 14(4):18808-19. PubMed ID: 26782531
[TBL] [Abstract][Full Text] [Related]
31. Long noncoding RNA MALAT1 associates with the malignant status and poor prognosis in glioma.
Ma KX; Wang HJ; Li XR; Li T; Su G; Yang P; Wu JW
Tumour Biol; 2015 May; 36(5):3355-9. PubMed ID: 25613066
[TBL] [Abstract][Full Text] [Related]
32. A commentary on "Long non-coding RNA MALAT1 as a valuable biomarker for prognosis in osteosarcoma: A systematic review and meta-analysis" (Int J Surg 2019;72:206-213).
Roy G; Roy P
Int J Surg; 2020 Feb; 74():27-28. PubMed ID: 31862257
[No Abstract] [Full Text] [Related]
33. CCEPR is a novel clinical biomarker for prognosis and regulates cell proliferation through PCNA in osteosarcoma.
Teng J; Guo X; Wang H
J Cell Biochem; 2019 Aug; 120(8):12796-12802. PubMed ID: 30861164
[TBL] [Abstract][Full Text] [Related]
34. LncRNA FAL1 is a negative prognostic biomarker and exhibits pro-oncogenic function in osteosarcoma.
Wang Y; Zhao Z; Zhang S; Li Z; Li D; Yang S; Zhang H; Zeng X; Liu J
J Cell Biochem; 2018 Nov; 119(10):8481-8489. PubMed ID: 29987852
[TBL] [Abstract][Full Text] [Related]
35. Increased expression of lncRNA HULC indicates a poor prognosis and promotes cell metastasis in osteosarcoma.
Sun XH; Yang LB; Geng XL; Wang R; Zhang ZC
Int J Clin Exp Pathol; 2015; 8(3):2994-3000. PubMed ID: 26045809
[TBL] [Abstract][Full Text] [Related]
36. [Prognostic value and mechanism of long non-coding RNA DLEU1 in osteosarcoma].
Zhang JJ; Yang P; Shang XQ
Zhongguo Gu Shang; 2023 Jun; 36(6):559-64. PubMed ID: 37366099
[TBL] [Abstract][Full Text] [Related]
37. Identification of N6-methylandenosine related LncRNAs biomarkers associated with the overall survival of osteosarcoma.
Zhang P; Xu K; Wang J; Zhang J; Quan H
BMC Cancer; 2021 Dec; 21(1):1285. PubMed ID: 34852770
[TBL] [Abstract][Full Text] [Related]
38. The lncRNA MALAT1 is a novel biomarker for gastric cancer metastasis.
Xia H; Chen Q; Chen Y; Ge X; Leng W; Tang Q; Ren M; Chen L; Yuan D; Zhang Y; Liu M; Gong Q; Bi F
Oncotarget; 2016 Aug; 7(35):56209-56218. PubMed ID: 27486823
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of long non-coding RNA FOXD2-AS1 expression in patients with solid tumors.
Zhou L; Li Z; Shao X; Yang B; Feng J; Xu L; Teng Y
Pathol Res Pract; 2019 Sep; 215(9):152449. PubMed ID: 31378453
[TBL] [Abstract][Full Text] [Related]
40. XB130 expression in human osteosarcoma: a clinical and experimental study.
Wang X; Wang R; Liu Z; Hao F; Huang H; Guo W
Int J Clin Exp Pathol; 2015; 8(3):2565-73. PubMed ID: 26045762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
